Remote Ischemic Conditioning is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury. Remote Ischemic Conditioning has been tested in myocardial infarction, stroke, and cardiac surgery settings, involving thousands of participants proving to be extremely safe. Remote Ischemic Conditioning is implemented by using a non-invasive tool similar to a blood pressure device and can be applied by the patient itself at home.
The main hypothesis of RESILIENCE trial is that the application of weekly Remote Ischemic Conditioning during the span of the chemotherapy duration will reduce the incidence of anthracycline-induced cardiotoxicity and heart failure. This hypothesis is based on strong pre-clinical data. In an experimental model, the implementation of Remote Ischemic Conditioning before each administration of anthracyclines resulted in a massive protection against the development of heart failure.
Protocol of Remote Ischemic Conditioning in RESILIENCE: 4 cycles of 5-min inflation / 5 min deflation of the arm cuff